Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million to fund clinical trials and other operational needs [1][3]. Group 1: Initial Public Offering Details - The company closed its initial public offering of 3,375,000 shares at a price of $4.00 per share, with trading commencing on May 9, 2025 [1]. - Gross proceeds from the offering amounted to $13.5 million before expenses [1]. - Underwriters were granted a 45-day option to purchase an additional 506,250 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a Phase III clinical trial for knee osteoarthritis [3]. - The company plans to initiate at least one non-registered corporate sponsorship study in multiple sclerosis [3]. - Proceeds will also be allocated for manufacturing its product candidate and general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin with potential therapeutic effects [6]. - The product is being developed as a treatment for knee pain in osteoarthritis patients who do not respond adequately to conventional therapies [6].

Company Overview - Perimeter Acquisition Corp. I is a special purpose acquisition company targeting companies in the defense and national security sectors, leveraging its management's extensive investment and operational experience [5] - The company also aims to explore opportunities at the intersection of defense, technology, and national security, believing its management team can drive value creation post-business combination [5] Initial Public Offering (IPO) Details - The company announced the pricing of its upsized initial public offering of 21,000,000 units at $10.00 per unit, with units expected to trade on Nasdaq under the ticker symbol "PMTRU" starting May 13, 2025 [1] - The offering is anticipated to close on May 14, 2025, subject to customary closing conditions, with Citigroup Global Markets Inc. serving as the sole book-running manager [2] - An additional 3,150,000 units may be purchased by the underwriter to cover over-allotments [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to these securities has been filed with the SEC and was declared effective on May 12, 2025, with the offering being made only by means of a prospectus [3]

Company Transitioned onto the OTC PinkCRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series ...

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the offering, b ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (the “Company”) announced today the closing of its initial public offering of 14,375,000 units, including the exercise in full of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $143,750,000. The units are listed on the Nasdaq Global Market (the “Nasdaq”) and commenced trading under the ticker symbol “IPODU” on May 7, 2025. Each unit consists of one Class A ordinary ...

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has grant ...

【环球网财经综合报道】2025年5月7日，中国证监会发布《推动公募基金高质量发展行动方案》（简称《行动方案》），是为通过 全面深化改革，强化公募基金行业与投资者的利益绑定，增强公募基金投资行为的稳定性，提升公募基金服务投资者的能力，发展 壮大权益类公募基金，进而更好发挥行业功能。 近年来，行业主动管理权益类基金业绩波动较大，部分产品频繁追逐热点，甚至出现风格漂移等现象，《行动方案》就是要强化业 绩比较基准的约束作用，解决这一问题。 "对主动管理权益类基金，推行与基金业绩表现挂钩的浮动管理费率收取模式"是《行动 方案》的要点之一。 根据《行动方案》，对于符合一定持有期要求的投资者，根据其持有期间产品业绩表现适用差异化的管理费率。业绩明显低于比较 基准的，须少收管理费，有力扭转基金公司"旱涝保收"的现象。 据悉，对主动管理权益类基金大力推行浮动管理费率，是本次公募基金改革的一个积极探索，为确保改革符合市场情况，证监会将 稳慎推进具体落地工作。 薪酬管理方面，《行动方案》提出系统完善基金公司考核评价制度，强化基金公司、高管、基金经理与投资者的利益绑定，督促行 业机构牢固树立以投资者最佳利益为核心的经营理念。 《行动 ...

Core Viewpoint - WF Holding Limited has successfully completed a partial exercise of the over-allotment option in its initial public offering, resulting in additional gross proceeds of US$960,000, bringing the total gross proceeds to approximately US$8.96 million [1][2]. Group 1: Offering Details - The underwriters purchased an additional 240,000 ordinary shares at a public offering price of US$4.00 per share [1]. - After the partial exercise, the total number of ordinary shares sold increased to 2,240,000 [2]. - The ordinary shares began trading on the Nasdaq Capital Market on March 27, 2025, under the ticker symbol "WFF" [2]. Group 2: Underwriters and Legal Counsel - Dominari Securities LLC acted as the lead underwriter, while Revere Securities LLC served as a co-underwriter for the offering [2]. - Bevilacqua PLLC acted as U.S. counsel to the company, and The Crone Law Group, P.C. acted as U.S. counsel to the underwriters [2]. Group 3: Company Overview - WF Holding Limited is a Malaysia-based manufacturer of fiberglass reinforced plastic (FRP) products, certified under ISO 9001:2015 [5]. - The company has over 30 years of experience in designing and fabricating FRP products, including tanks, pipes, and ducts [5]. - WF Holding focuses on delivering high-quality and durable products that enhance industrial infrastructure resilience and sustainability [5].

Core Viewpoint - Theriva Biologics announced a public offering of up to 6,818,180 shares of common stock and warrants, aiming to raise approximately $7.5 million for working capital and R&D purposes [1][2]. Group 1: Offering Details - The offering price is set at $1.10 per share and accompanying warrant, with warrants exercisable immediately and expiring five years from issuance [1]. - The closing of the offering is expected on or about May 8, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes, including research and development and manufacturing scale-up [2]. - The company may also consider using a portion of the proceeds for investments or acquisitions, although no commitments currently exist [2]. Group 3: Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].

$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with participation from new and existing healthcare focused institutional ...